Neuralstem almost to third base with NSI-566 for Lou Gehrig's Disease...
Neuralstem (NASDAQ:CUR) recently finished up their Phase 2 trial for ALS using their NSI-566 Neural Stem Cells on July 30th, according to a newly released video by the Michigan ALS Association. In that video, Dr. Eva Feldman gives a presentation on her work and a tiny glimpse into what we can expect from the Phase 2 results, and a probable upcoming Phase 3 trial.
In her video, Dr. Feldman discusses the end of the Phase 2 trial occurring on July 30th and her locking the data and sending it over to the FDA on August 4th. She states that she is "jazzed" about sending the data to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|